PACTR202201721209443尚未招募3 期
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 1,700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Histologically confirmed invasive breast carcinoma
- •-Centrally-confirmed human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer
- •-Centrally confirmed PD-L1 and hormone receptor status
- •-Clinical stage at disease presentation: cT4/anyN/M0, any cT/N2-3/M0, or cT1-3/N0-1/M0 (participants with cT1mi/T1a/T1b/N0 are not eligible)
- •-Completion of pre-operative systemic chemotherapy including at least 9 weeks of taxane and 9 weeks of trastuzumab (anthracycline and/or additional HER2-targeted agents are permitted)
- •<=12 weeks between primary surgery and randomization
- •-Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- •-Screening left ventricular ejection fraction (LVEF) >= 50% and no decrease in LVEF by >15% from the pre-chemotherapy LVEF. If no pre-chemotherapy LVEF, screening LVEF >= 55%
- •-Life expectancy >= 6 months
- •-Adequate hematologic and end organ function
排除标准
- •-Stage IV breast cancer
- •-An overall response of disease progression according to the investigator at the conclusion of preoperative systemic therapy
- •-Prior treatment with T-DM1, or atezolizumab, or other immune checkpoint inhibitors
- •-History of exposure to various cumulative doses of anthracyclines
- •-History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or ductal carcinoma in situ (DCIS)
- •-Current grade >=2 peripheral neuropathy
- •-History of idiopathic pulmonary fibrosis, organizing pneumonia, or pneumonitis
- •-History of or active autoimmune disease or immune deficiency
- •-Treatment with immunostimulatory or immunosuppressive agents
- •-Cardiopulmonary dysfunction
- •-Any known active liver disease
研究者
相似试验
进行中（未招募）
1 期
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's diseaseEUCTR2014-003824-36-SEF. Hoffmann-La Roche Ltd1,250
进行中（未招募）
1 期
A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate CancerEUCTR2016-004429-17-NOF. Hoffmann-La Roche Ltd1,101
进行中（未招募）
不适用
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's diseaseEUCTR2014-003824-36-ESRoche Farma S.A en nombre de F. Hoffmann-La Roche Ltd1,250
已完成
不适用
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATIOPER-062-13F. HOFFMANN-LA ROCHE LTD.,11
进行中（未招募）
1 期
A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer.Small cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003301-97-PLF. Hoffmann-La Roche Ltd470